- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Rolapitant Gains FDA Approval for CINV
Rolapitant was approved to prevent delayed phase chemotherapy-induced nausea and vomiting in adult patients.
The FDA today approved rolapitant (Varubi) to prevent delayed phase chemotherapy-induced nausea and vomiting, which are commonly in cancer patients receiving chemotherapy.
The substance P/neurokinin-1 receptor antagonist rolapitant has been approved in adults for use in combination with other antiemetic agents that prevent nausea and vomiting associated with initial and repeat courses of vomit-inducing cancer chemotherapy according to the FDA's press release.
“Chemotherapy-induced nausea and vomiting remains a major issue that can disrupt patients' lives and sometimes their therapy,” said Amy Egan, MD, MPH, deputy director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research. “Today’s approval provides cancer patients with another treatment option for the prevention of the delayed phase of nausea and vomiting caused by chemotherapy.”
Read the cmplete press release here: http://1.usa.gov/1KHX8jU
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More
Higher UTI Risk After Spinal Fusion in Patients With Certain Comorbidities
March 5th 2025A study investigated the incidence of postoperative urinary tract infections (UTIs) in patients undergoing spinal fusion for deformities, finding that patients with more than 12 levels fused had the highest UTI rates.
Read More
